

## Standard Homeopathic Company Secures \$40 Million Credit Facility from Hayfin

Torreya served as financial advisor to SHC in the transaction

Los Angeles, CA June 7, 2018

Standard Homeopathic Company (SHC) has entered into a \$40mm term loan agreement with Hayfin Capital Management. SHC, through its subsidiary Hyland's, Inc., develops and manufactures homeopathic medicines in the United States. It offers products for various ailments, such as stress, sleep, pain relief, women's health, digestion, first aid, and pediatric cough & cold. The company offers its products through chain drug stores, pharmacies, grocery stores, natural product stores, and supercenters. Standard Homeopathic Company was founded in 1903.

This non-dilutive capital allows SHC to retire existing indebtedness and invest in marketing and product development initiatives to promote further growth. Hyland's is the largest manufacturer of homeopathic medicines in the United States and a brand name recognized by over 50% of mothers in America.

Torreya's Capital Markets team served as financial advisor to Standard Homeopathic in the financing. Our team continues to be dedicated to raising capital for our corporate clients via equity, debt and royalty monetizations. This transaction marks a continued expansion of Torreya's healthcare advisory efforts into the OTC and consumer space. Torreya has advised on 14 financing transactions in the healthcare industry in the last 24 months.

### ABOUT STANDARD HOMEOPATHIC/HYLAND'S

For more information about SHC/Hyland's, please see: [www.hylands.com](http://www.hylands.com)

### ABOUT HAYFIN CAPITAL MANAGEMENT LLP

For more information about Hayfin, please see: [www.hayfin.com](http://www.hayfin.com)



### Torreya Contact

**TOM BABICH**

Head of Capital Markets | New York Office

[tom.babich@torreya.com](mailto:tom.babich@torreya.com) | 212.257.5811 | [torreya.com](http://torreya.com)

Torreya is a global advisory firm serving the life sciences industry. Please visit [torreya.com](http://torreya.com) for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 150 Aldersgate Street, London EC1A 4AB. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.